Provided by Tiger Trade Technology Pte. Ltd.

Royalty Pharma plc

38.31
-0.0700-0.18%
Post-market: 38.310.00000.00%16:46 EST
Volume:2.25M
Turnover:86.73M
Market Cap:22.34B
PE:21.87
High:38.90
Open:38.38
Low:38.30
Close:38.38
52wk High:41.24
52wk Low:24.05
Shares:583.17M
Float Shares:379.85M
Volume Ratio:0.40
T/O Rate:0.59%
Dividend:0.87
Dividend Rate:2.27%
EPS(TTM):1.75
EPS(LYR):1.92
ROE:13.11%
ROA:5.22%
PB:3.48
PE(LYR):19.99

Loading ...

Jun 02, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 22, 2023

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
May 09, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 09, 2023

Major Issues Report

8-K - Current report
Mar 28, 2023

Major Issues Report

8-K - Current report
Mar 15, 2023

Major Issues Report

8-K - Current report
Feb 15, 2023

Annual Report

10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 15, 2023

Major Issues Report

8-K - Current report
Feb 13, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 09, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Feb 09, 2023

Beneficial Ownership Change

SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals
Jan 09, 2023

Major Issues Report

8-K - Current report
Dec 01, 2022

Major Issues Report

8-K - Current report
Nov 08, 2022

Major Issues Report

8-K - Current report
Nov 08, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]
Oct 04, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Oct 03, 2022

Major Issues Report

8-K - Current report
Aug 11, 2022

Beneficial Ownership Change

SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
Aug 04, 2022

Major Issues Report

8-K - Current report
Aug 04, 2022

Quarterly Report

10-Q - Quarterly report [Sections 13 or 15(d)]